Randomized Trial: Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes
22 Nov, 2018 | 21:20h | UTCCommentary: Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk – Endocrinology Advisor (free)